2025 Nebraska Congress on Hematologic Malignancies: Recent Advances and Cellular Therapy
The 2025 Nebraska Congress on Hematologic Malignancies: Recent Advances and Cellular Therapy is a CME-accredited, in-person hematology conference featuring leading hematology experts. Expert faculty will place recent updates into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.
This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.
Target Audience
- Hematologists/Oncologists
- Oncology Nurse Practitioners
- Oncology Pharmacists
- Oncology Physician Assistants
- Oncology Fellows/Residents
- Oncology Nurses
- Researchers and others involved in the care of cancer patients
Organizing Committee
Conference Director:
Dr. Binay Shah - Binaytara Foundation
Conference Co-Chairs:
Dr. Christopher D'Angelo - University of Nebraska Medical Center
Dr. Krishna Gundabolu - University of Nebraska Medical Center
Organizing Committee
Dr. Joel Michalski - Nebraska Cancer Specialists
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review recent updates & discuss their applications in clinical settings.
- Choose new therapeutic options for treating benign and malignant hematologic disorders, understanding appropriate indications and contraindications to these therapeutic approaches.
- Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and hematology patients.
- Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.
Hotel Room Reservation
A limited number of guestrooms are reserved at the Hilton Omaha for the participants of this meeting at a discounted rate of $154 per night. The room rate does not include any additional fees or applicable taxes.
CUTOFF - Tuesday, March 11, 2025.
Please use the link below to reserve your room for the discounted rate. The rate is good through Tuesday, March 11, 2025.
Link coming soon...
Parking
Daily Self-Parking- $5 per hour with a daily maximum of $35
Overnight Self-Parking at $29.00 per-day. Overnight Valet Parking at $40 per-day
Saturday, April 12, 2025
All times below are listed in Central Daylight Time (CDT).
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
08:00 AM – 08:05 AM Welcome
08:05 AM – 08:30 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD
08:30 AM – 09:25 AM Session 1: Acute Leukemia
Session Chair: Steven Dunder, MD
08:30 AM – 08:50 AM Induction Strategies for Fit and Frail Acute Myeloid Leukemia - Michael Haddadin, MD
08:50 AM – 09:10 AM Targeted Agents for Relapsed and Refractory AML - Stacey Knox, MD
09:10 AM – 09:25 AM Panel Discussion
09:25 AM – 10:20 AM Session 2: Non-Hodgkin Lymphoma
Session Chair: Christopher R. D'Angelo, MD
09:25 AM – 09:45 AM Best Strategy for Newly Diagnosed Hodgkin Lymphoma - Fahed Rabih C MD
09:45 AM – 10:05 AM Initiation of Bispecific Antibody Therapy for Relapsed DLBCL - Kailash Mosalpuria, MD, MPH, FACP
10:05 AM – 10:20 AM Panel Discussion
10:20 AM – 10:50 AM Break & Exhibits
10:50 AM – 11:45 AM Session 3: Multiple Myeloma
Session Chair: Soe Min Tun, MD, MBA, MSc
10:50 AM – 11:10 AM Management and Induction Strategies for Newly Diagnosed Multiple Myeloma - Eric J. Avery, MD
11:10 AM – 11:30 AM Use Transplant and Maintenance in Multiple Myeloma
11:30 AM – 11:40 AM Panel Discussion
11:45 AM – 12:40 PM Session 4 : Classical Hematology
Session Chair: Marcel P Devetten, MD
11:45 AM – 12:05 AM Gene therapies for Hemophilia and Hemoglobinopathies - Alex Nester, MD
12:05 AM – 12:25 PM Rural Challenges in the Care of Patients with Hematologic Malignancies - Laxmi Narayana R. Buddharaju, MD
12:25 PM – 12:40 PM Panel Discussion
12:40 PM – 01:40 PM Lunch & Exhibits
01:40 PM – 02:35 PM Session 5: Myeloid Malignancies
Session Chair: Mehmet Sitki Copur, MD, FACP
01:40 PM – 02:00 PM Best Practice for Newly Diagnosed ET and PV - Peter Silberstein, MD
02:00 PM – 02:20 PM Treating the Frail Patient with Newly Diagnosed Myelodysplastic Syndrome
02:20 PM – 02:35 PM Panel Discussion
02:35 PM – 03:05 PM Break & Exhibits
03:05 PM – 04:10 PM Session 6: CAR-T cell therapy
Session Chair: Joel Michalski, MD, PHD
03:05 PM – 03:25 PM The Who, What, When, Where and Why of CAR T Cell Therapy for Non-Hodgkin Lymphoma in 2024 - Snegha Ananth, MBBS
03:25 PM – 03:45 PM When to Use BCMA CAR T-Cell Therapy in Multiple Myeloma
03:45 PM – 04:00 PM Panel Discussion
04:00 PM Adjourn
Hotel Room Reservation
A limited number of guestrooms are reserved at the Hilton Omaha for the participants of this meeting at a discounted rate of $154 per night. The room rate does not include any additional fees or applicable taxes.
CUTOFF - Tuesday, March 11, 2025.
Please use the link below to reserve your room for the discounted rate. The rate is good through Tuesday, March 11, 2025.
Link coming soon...
Parking
Daily Self-Parking- $5 per hour with a daily maximum of $35
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Steven Dunder
SOE MIN TUN
Joel Michalski, MD PhD
Available Credit
- 5.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 5.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 5.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.